Pei Hui

Genetic Stability of Short Tandem Repeat (STR) Loci in Human Term Placentas.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: June 25, 2026

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Journal: Gynecologic oncology

Published: June 19, 2026

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Journal: Gynecologic oncology reports

Published: June 03, 2026

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Journal: Gynecologic oncology

Published: May 29, 2026

Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy.

Journal: JAMA network open

Published: February 02, 2026

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: January 27, 2026

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 14, 2026

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 14, 2026

Endometrial carcinomas - Challenges and updates on selected topics.

Journal: Human pathology

Published: December 04, 2025

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Journal: Gynecologic oncology

Published: December 02, 2025

Genetic Stability of Short Tandem Repeat (STR) Loci in Human Term Placentas.

Genetic Stability of Short Tandem Repeat (STR) Loci in Human Term Placentas.

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy.

Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy.

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Integrated mutational landscape analysis of endometrial stromal sarcoma.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Endometrial carcinomas - Challenges and updates on selected topics.

Endometrial carcinomas - Challenges and updates on selected topics.

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Uterine teratomas: a report of clinicopathological features of five tumours.

Uterine teratomas: a report of clinicopathological features of five tumours.